Table 3.

Clinical outcomes of studies utilising platelet-rich plasma

Study	Type of Osteotomy Performed	Intervention	Number of Patients in Intervention Group	Number of Patients in Control Group	Number of Patients undergoing second-look Arthroscopy	Pre-OP VAS Score	Post-OP VAS score	Pre-OP Kanamiya Grading	Post-Op Kanamiya Grading	Pre-OP Lysholm Score	Post-OP Lysholm Score	Pre-OP KOOS Score	Post-OP KOOS Score
D’Elia et al, Revista Brasileira de Ortopedia 2015 [19]	HTO	PRP with BMAC	11	14	N.A	Not Reported		Not Reported	Not Reported	Not Reported	Not Reported	Not Reported	Not Reported
Koh et al, Arthroscopy 2014 [21]	HTO	PRP with Adipose- derived MSC	21	23	44/44 patients at mean 19.8 months post-op	PRP (control) (n = 23) v PRP-MSC (n = 21) 45.4 ± 7.1 v 44.3 ± 5.7		Not Reported	PRP (control) (n = 23) v PRP-MSC (n = 21) Grade I: 11 (47.8%) v 1 (4.8%) Grade II: 11 (47.8%) v 9 (42.9%) Grade III: 1 (4.3%) v 8 (38.1%) Grade IV: 0 (0%) v 3 (14.3%)	PRP (control) (n = 23) v PRP-MSC (n = 21) 56.7 ± 12.2 v 55.7 ± 11.5	PRP (control) (n = 23) v PRP-MSC (n = 21) At latest follow-up (mean 24.6 months (PRP) and 24.2 months (PRP-MSC)) 80.6 ± 13.5 v 84.7 ± 16.2	Not Reported	PRP (control) (n = 23) v PRP-MSC (n = 21) At latest follow-up (mean 24.6 months (PRP) and 24.2 months (PRP-MSC)): Pain subscale: 74.0 ± 5.7 v 81.2 ± 6.9 Symptom subscale: 75.4 ± 8.5 v 82.8 ± 7.2

VAS Visual Analogue Scale, KOOS Knee injury and Osteoarthritis Outcome Score, HTO High Tibial Osteotomy, MSCs Mesenchymal Stem Cells, PRP Platelet-Rich Plasma, BMAC Bone Marrow Aspirate Concentrate